NIH will partner drug industry to study Alzheimer's, diabetes, and autoimmune disorders
Michael R. McCarthy · BMJ · 2014
The US National Institutes of Health (NIH) will partner 10 biopharmaceutical companies to identify promising drug targets and disease biomarkers, the agency announced on 4 February. Eight nonprofit organizations will also participate in the collaboration. The initiative, called the Accelerating Medicines Partnership, will initially focus on biomarkers and drug targets for Alzheimer’s disease, type 2 diabetes, and the autoimmune disorders of rheumatoid arthritis and systemic erythematosus. All data and analyses generated by the initiative will be made publicly available “to the broad biomedical community,” the NIH said. In a …